A
Audrey L. Shaw
Researcher at Salix Pharmaceuticals
Publications - 24
Citations - 2042
Audrey L. Shaw is an academic researcher from Salix Pharmaceuticals. The author has contributed to research in topics: Rifaximin & Hepatic encephalopathy. The author has an hindex of 8, co-authored 24 publications receiving 1837 citations.
Papers
More filters
Journal ArticleDOI
Rifaximin treatment in hepatic encephalopathy.
Nathan M. Bass,Kevin D. Mullen,Arun J. Sanyal,Fred Poordad,Guy W. Neff,Carroll B. Leevy,Samuel H. Sigal,Muhammad Y. Sheikh,Kimberly Beavers,Todd Frederick,Lewis W. Teperman,Donald J. Hillebrand,Shirley Huang,Kunal Merchant,Audrey L. Shaw,Enoch Bortey,William P. Forbes +16 more
TL;DR: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo, and also significantly reduced the risk of hospitalization involving hepaticEncephalopathy.
Journal ArticleDOI
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Mark Pimentel,Anthony Lembo,William D. Chey,Salam Zakko,Yehuda Ringel,Jing Yu,Shadreck M. Mareya,Audrey L. Shaw,Enoch Bortey,William P. Forbes +9 more
TL;DR: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.
Journal ArticleDOI
Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial.
Gary R. Lichtenstein,G. L. Gordon,Salam Zakko,Uma K. Murthy,S. Sedghi,Ronald E. Pruitt,Kunal Merchant,Audrey L. Shaw,Enoch Bortey,William P. Forbes +9 more
TL;DR: Aliment Pharmacol Ther 2010; 32: 990–999
Journal ArticleDOI
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Ellen Scherl,Ronald E. Pruitt,Glenn L. Gordon,Mark Lamet,Audrey L. Shaw,Shirley Huang,Shadreck M. Mareya,William P. Forbes +7 more
TL;DR: Balsalazide disodium disodium 1.1’g tablets administered as 3.3 g twice daily are effective, well tolerated and significantly better than placebo for improving signs and symptoms of mild-to-moderately-active UC.
Journal ArticleDOI
Prevention of Travelers' Diarrhea With Rifaximin in US Travelers to Mexico
Francisco Martinez-Sandoval,Charles D. Ericsson,Zhi-Dong Jiang,Pablo C. Okhuysen,Pablo C. Okhuysen,Juan H.M. Meléndez Romero,Norma Hernandez,William P. Forbes,Audrey L. Shaw,Enoch Bortey,Herbert L. DuPont +10 more
TL;DR: Prophylactic treatment with rifaximin 600 mg/d for 14 days safely and effectively reduced the risk of developing TD in US travelers to Mexico.